Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
early-stage  ||| S:13 E:25 ||| JJ
erythematotelangiectatic  ||| S:25 E:50 ||| JJ
rosacea  ||| S:50 E:58 ||| NN
with  ||| S:58 E:63 ||| IN
a  ||| S:63 E:65 ||| DT
Q-switched  ||| S:65 E:76 ||| JJ
595-nm  ||| S:76 E:83 ||| NNP
Nd ||| S:83 E:85 ||| NNP
: ||| S:85 E:86 ||| :
YAG  ||| S:86 E:90 ||| FW
laser  ||| S:90 E:96 ||| FW
Erythematotelangiectatic  ||| S:96 E:121 ||| FW
rosacea  ||| S:121 E:129 ||| FW
presents  ||| S:129 E:138 ||| VBZ
as  ||| S:138 E:141 ||| RB
persistent  ||| S:141 E:152 ||| JJ
erythema  ||| S:152 E:161 ||| NN
and  ||| S:161 E:165 ||| CC
telangiectasia  ||| S:165 E:180 ||| NN
with  ||| S:180 E:185 ||| IN
frequent  ||| S:185 E:194 ||| JJ
flushing  ||| S:194 E:203 ||| NN
and  ||| S:203 E:207 ||| CC
blushing  ||| S:207 E:216 ||| NN
on  ||| S:216 E:219 ||| IN
the  ||| S:219 E:223 ||| DT
facial  ||| S:223 E:230 ||| JJ
and  ||| S:230 E:234 ||| CC
extrafacial  ||| S:234 E:246 ||| JJ
skin ||| S:246 E:250 ||| NN
.  ||| S:250 E:252 ||| .
Additionally ||| S:252 E:264 ||| RB
,  ||| S:264 E:266 ||| ,
papulopustular  ||| S:266 E:281 ||| FW
rosacea  ||| S:281 E:289 ||| FW
shows  ||| S:289 E:295 ||| FW
acneiform  ||| S:295 E:305 ||| FW
papules ||| S:305 E:312 ||| FW
,  ||| S:312 E:314 ||| ,
pustules ||| S:314 E:322 ||| NN
,  ||| S:322 E:324 ||| ,
and  ||| S:324 E:328 ||| CC
nodules  ||| S:328 E:336 ||| NN
with  ||| S:336 E:341 ||| IN
persistent  ||| S:341 E:352 ||| JJ
plaque-form  ||| S:352 E:364 ||| JJ
edema ||| S:364 E:369 ||| NN
.  ||| S:369 E:371 ||| .
Despite  ||| S:371 E:379 ||| IN
garnering  ||| S:379 E:389 ||| VBG
only  ||| S:389 E:394 ||| RB
grade-C  ||| S:394 E:402 ||| JJ
or  ||| S:402 E:405 ||| CC
-D  ||| S:405 E:408 ||| JJ
level  ||| S:408 E:414 ||| NN
recommendations ||| S:414 E:429 ||| NNS
,  ||| S:429 E:431 ||| ,
a  ||| S:431 E:433 ||| DT
585-nm  ||| S:433 E:440 ||| NNP
or  ||| S:440 E:443 ||| CC
595-nm  ||| S:443 E:450 ||| CD
flashlamp-pumped  ||| S:450 E:467 ||| JJ
pulsed-dye  ||| S:467 E:478 ||| JJ
laser  ||| S:478 E:484 ||| NN
can  ||| S:484 E:488 ||| MD
be  ||| S:488 E:491 ||| VB
considered  ||| S:491 E:502 ||| VBN
as  ||| S:502 E:505 ||| IN
an  ||| S:505 E:508 ||| DT
effective  ||| S:508 E:518 ||| JJ
therapeutic  ||| S:518 E:530 ||| JJ
modality  ||| S:530 E:539 ||| NN
for  ||| S:539 E:543 ||| IN
the  ||| S:543 E:547 ||| DT
treatment  ||| S:547 E:557 ||| NN
of  ||| S:557 E:560 ||| IN
rosacea  ||| S:560 E:568 ||| NN
in  ||| S:568 E:571 ||| IN
patients  ||| S:571 E:580 ||| NNS
who  ||| S:580 E:584 ||| WP
are  ||| S:584 E:588 ||| VBP
refractory  ||| S:588 E:599 ||| VBN
to  ||| S:599 E:602 ||| TO
topical  ||| S:602 E:610 ||| VB
and ||| S:610 E:613 ||| CC
/ ||| S:613 E:614 ||| NNP
or  ||| S:614 E:617 ||| CC
systemic  ||| S:617 E:626 ||| JJ
treatments ||| S:626 E:636 ||| NNS
.  ||| S:636 E:638 ||| .
In  ||| S:638 E:641 ||| IN
this  ||| S:641 E:646 ||| DT
report ||| S:646 E:652 ||| NN
,  ||| S:652 E:654 ||| ,
treatment  ||| S:654 E:664 ||| NN
with  ||| S:664 E:669 ||| IN
a  ||| S:669 E:671 ||| DT
Q-switched  ||| S:671 E:682 ||| JJ
595-nm  ||| S:682 E:689 ||| FW
neodymium-doped  ||| S:689 E:705 ||| FW
yttrium  ||| S:705 E:713 ||| FW
aluminum  ||| S:713 E:722 ||| FW
garnet  ||| S:722 E:729 ||| FW
( ||| S:729 E:730 ||| -LRB-
Nd ||| S:730 E:732 ||| NNP
: ||| S:732 E:733 ||| :
YAG ||| S:733 E:736 ||| NNP
)  ||| S:736 E:738 ||| -RRB-
laser  ||| S:738 E:744 ||| NN
with  ||| S:744 E:749 ||| IN
low  ||| S:749 E:753 ||| JJ
non-purpuragenic  ||| S:753 E:770 ||| JJ
fluence  ||| S:770 E:778 ||| NN
proved  ||| S:778 E:785 ||| VBD
to  ||| S:785 E:788 ||| TO
be  ||| S:788 E:791 ||| VB
safe  ||| S:791 E:796 ||| JJ
and  ||| S:796 E:800 ||| CC
effective  ||| S:800 E:810 ||| JJ
in  ||| S:810 E:813 ||| IN
treating  ||| S:813 E:822 ||| VBG
early-stage  ||| S:822 E:834 ||| JJ
erythematotelangiectatic  ||| S:834 E:859 ||| JJ
rosacea  ||| S:859 E:867 ||| NN
in  ||| S:867 E:870 ||| IN
two  ||| S:870 E:874 ||| CD
female  ||| S:874 E:881 ||| JJ
Korean  ||| S:881 E:888 ||| JJ
patients ||| S:888 E:896 ||| NNS
.  ||| S:896 E:898 ||| .
Laser  ||| S:898 E:904 ||| NN
treatment  ||| S:904 E:914 ||| NN
for  ||| S:914 E:918 ||| IN
rosacea  ||| S:918 E:926 ||| NN
was  ||| S:926 E:930 ||| VBD
delivered  ||| S:930 E:940 ||| VBN
with  ||| S:940 E:945 ||| IN
the  ||| S:945 E:949 ||| DT
settings  ||| S:949 E:958 ||| NNS
of  ||| S:958 E:961 ||| IN
pulse  ||| S:961 E:967 ||| JJ
energy  ||| S:967 E:974 ||| NN
of  ||| S:974 E:977 ||| IN
0.4-0.5  ||| S:977 E:985 ||| NNP
J ||| S:985 E:986 ||| NNP
/ ||| S:986 E:987 ||| FW
cm ||| S:987 E:989 ||| FW
( ||| S:989 E:990 ||| -LRB-
2 ||| S:990 E:991 ||| LS
) ||| S:991 E:992 ||| -RRB-
,  ||| S:992 E:994 ||| ,
pulse  ||| S:994 E:1000 ||| JJ
duration  ||| S:1000 E:1009 ||| NN
of  ||| S:1009 E:1012 ||| IN
5-10  ||| S:1012 E:1017 ||| JJ
ns ||| S:1017 E:1019 ||| NN
,  ||| S:1019 E:1021 ||| ,
5-mm  ||| S:1021 E:1026 ||| CD
spot  ||| S:1026 E:1031 ||| NN
size ||| S:1031 E:1035 ||| NN
,  ||| S:1035 E:1037 ||| ,
5  ||| S:1037 E:1039 ||| CD
Hz ||| S:1039 E:1041 ||| NNP
,  ||| S:1041 E:1043 ||| ,
and  ||| S:1043 E:1047 ||| CC
500  ||| S:1047 E:1051 ||| CD
shots ||| S:1051 E:1056 ||| NNS
.  ||| S:1056 E:1058 ||| .
Additionally ||| S:1058 E:1070 ||| RB
,  ||| S:1070 E:1072 ||| ,
we  ||| S:1072 E:1075 ||| PRP
found  ||| S:1075 E:1081 ||| VBD
that  ||| S:1081 E:1086 ||| DT
remarkable  ||| S:1086 E:1097 ||| JJ
therapeutic  ||| S:1097 E:1109 ||| JJ
effects  ||| S:1109 E:1117 ||| NNS
were  ||| S:1117 E:1122 ||| VBD
achieved  ||| S:1122 E:1131 ||| VBN
for  ||| S:1131 E:1135 ||| IN
both  ||| S:1135 E:1140 ||| DT
rosacea  ||| S:1140 E:1148 ||| NN
and  ||| S:1148 E:1152 ||| CC
melasma  ||| S:1152 E:1160 ||| NN
by  ||| S:1160 E:1163 ||| IN
combining  ||| S:1163 E:1173 ||| VBG
Q-switched  ||| S:1173 E:1184 ||| JJ
quick  ||| S:1184 E:1190 ||| JJ
pulse-to-pulse  ||| S:1190 E:1205 ||| JJ
1,064-nm  ||| S:1205 E:1214 ||| NNP
Nd ||| S:1214 E:1216 ||| NNP
: ||| S:1216 E:1217 ||| :
YAG  ||| S:1217 E:1221 ||| NNP
and  ||| S:1221 E:1225 ||| CC
Q-switched  ||| S:1225 E:1236 ||| NNP
595-nm  ||| S:1236 E:1243 ||| NNP
Nd ||| S:1243 E:1245 ||| NNP
: ||| S:1245 E:1246 ||| :
YAG  ||| S:1246 E:1250 ||| NNP
laser  ||| S:1250 E:1256 ||| NN
treatments ||| S:1256 E:1266 ||| NNS
,  ||| S:1266 E:1268 ||| ,
which  ||| S:1268 E:1274 ||| WDT
required  ||| S:1274 E:1283 ||| VBD
only  ||| S:1283 E:1288 ||| RB
the  ||| S:1288 E:1292 ||| DT
changing  ||| S:1292 E:1301 ||| VBG
of  ||| S:1301 E:1304 ||| IN
handpieces  ||| S:1304 E:1315 ||| VBG
equipped  ||| S:1315 E:1324 ||| VBN
with  ||| S:1324 E:1329 ||| IN
solid  ||| S:1329 E:1335 ||| JJ
dye ||| S:1335 E:1338 ||| NN
.  ||| S:1338 E:1340 ||| .
In  ||| S:1340 E:1343 ||| IN
conclusion ||| S:1343 E:1353 ||| NN
,  ||| S:1353 E:1355 ||| ,
we  ||| S:1355 E:1358 ||| PRP
suggest  ||| S:1358 E:1366 ||| VBP
that  ||| S:1366 E:1371 ||| DT
treatment  ||| S:1371 E:1381 ||| NN
with  ||| S:1381 E:1386 ||| IN
a  ||| S:1386 E:1388 ||| DT
Q-switched  ||| S:1388 E:1399 ||| JJ
595-nm  ||| S:1399 E:1406 ||| NNP
Nd ||| S:1406 E:1408 ||| NNP
: ||| S:1408 E:1409 ||| :
YAG  ||| S:1409 E:1413 ||| NNP
laser  ||| S:1413 E:1419 ||| NN
with  ||| S:1419 E:1424 ||| IN
low  ||| S:1424 E:1428 ||| JJ
fluence  ||| S:1428 E:1436 ||| NN
may  ||| S:1436 E:1440 ||| MD
provide  ||| S:1440 E:1448 ||| VB
an  ||| S:1448 E:1451 ||| DT
additional  ||| S:1451 E:1462 ||| JJ
therapeutic  ||| S:1462 E:1474 ||| JJ
option  ||| S:1474 E:1481 ||| NN
for  ||| S:1481 E:1485 ||| IN
treating  ||| S:1485 E:1494 ||| VBG
early-stage  ||| S:1494 E:1506 ||| JJ
erythematotelangiectatic  ||| S:1506 E:1531 ||| JJ
rosacea ||| S:1531 E:1538 ||| NN
.  ||| S:1538 E:1540 ||| .
